KRAS and non-small cell lung carcinoma: However, the KRYSTAL-1 clinical trial has evaluated the usefulness of adagrasib in 116 patients with metastatic non-small cell lung cancer in 116 patients with the KRAS G12C mutation, practically all of whom had received chemotherapy and immunotherapy.